Despite health department funding, Michigan has no state law explicitly authorizing SSP—but does have local ordinances against syringe access.
The new approval allows patients to transition to a single 200mg subcutaneous injection once every 4 weeks, following completion of the induction phase.
Learn more about the critical tests for ensuring the proper performance of auto-injectors, which are used for a variety of ...
5don MSN
Urgent warning after severely anorexic woman was prescribed weight loss jab by online pharmacy
A severely anorexic young woman was prescribed blockbuster weight loss jab Wegovy by one of the UK's biggest online ...
A coalition of news organizations is suing Tennessee’s top prisons official and a warden, alleging that state execution ...
Pharmaceutical Technology on MSN
FDA rejects Regeneron’s pre-filled Eylea HD syringes amid filling facility woes
Regeneron is planning to re-apply to the FDA with a new pre-filled syringe manufacturing filler in January 2026.
The MarketWatch News Department was not involved in the creation of this content. Vabysmo now covered across all three approved indications in the province, providing patients with a comprehensively ...
Royalty-free licenses let you pay once to use copyrighted images and video clips in personal and commercial projects on an ongoing basis without requiring additional payments each time you use that ...
The U.S. Food and Drug Administration (FDA) on Thursday approved a new option for patients to self-inject Argenx SE’s (NASDAQ:ARGX) Vyvgart Hytrulo with a prefilled syringe (efgartigimod alfa and ...
SAN DIEGO, April 10, 2025 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO) (Halozyme) today announced that argenx has received U.S. Food and Drug Administration (FDA) approval of VYVGART ® ...
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), today announced that the U.S. Food and Drug Administration (FDA) has approved the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results